5 results on '"Polakova, K. M."'
Number of results to display per page
Search Results
2. Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions
- Author
-
Silvestri, G, Trotta, R, Stramucci, L, Ellis, J, Harb, J, Neviani, P, Wang, S, Eisfeld, A, Walker, C, Zhang, B, Srutova, K, Gambacorti-Passerini, C, Pineda, G, Jamieson, C, Stagno, F, Vigneri, P, Nteliopoulos, G, May, P, Reid, A, Garzon, R, Roy, D, Moutuou, M, Guimond, M, Hokland, P, Deininger, M, Fitzgerald, G, Harman, C, Dazzi, F, Milojkovic, D, Apperley, J, Marcucci, G, Qi, J, Polakova, K, Zou, Y, Fan, X, Baer, M, Calabretta, B, Perrotti, D, Silvestri G., Trotta R., Stramucci L., Ellis J. J., Harb J. G., Neviani P., Wang S., Eisfeld A. -K., Walker C. J., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C. H. M., Stagno F., Vigneri P., Nteliopoulos G., May P. C., Reid A. G., Garzon R., Roy D. -C., Moutuou M. M., Guimond M., Hokland P., Deininger M. W., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J. F., Marcucci G., Qi J., Polakova K. M., Zou Y., Fan X., Baer M. R., Calabretta B., Perrotti D., Silvestri, G, Trotta, R, Stramucci, L, Ellis, J, Harb, J, Neviani, P, Wang, S, Eisfeld, A, Walker, C, Zhang, B, Srutova, K, Gambacorti-Passerini, C, Pineda, G, Jamieson, C, Stagno, F, Vigneri, P, Nteliopoulos, G, May, P, Reid, A, Garzon, R, Roy, D, Moutuou, M, Guimond, M, Hokland, P, Deininger, M, Fitzgerald, G, Harman, C, Dazzi, F, Milojkovic, D, Apperley, J, Marcucci, G, Qi, J, Polakova, K, Zou, Y, Fan, X, Baer, M, Calabretta, B, Perrotti, D, Silvestri G., Trotta R., Stramucci L., Ellis J. J., Harb J. G., Neviani P., Wang S., Eisfeld A. -K., Walker C. J., Zhang B., Srutova K., Gambacorti-Passerini C., Pineda G., Jamieson C. H. M., Stagno F., Vigneri P., Nteliopoulos G., May P. C., Reid A. G., Garzon R., Roy D. -C., Moutuou M. M., Guimond M., Hokland P., Deininger M. W., Fitzgerald G., Harman C., Dazzi F., Milojkovic D., Apperley J. F., Marcucci G., Qi J., Polakova K. M., Zou Y., Fan X., Baer M. R., Calabretta B., and Perrotti D.
- Abstract
Persistence of drug-resistant quiescent leukemic stem cells (LSC) and impaired natural killer (NK) cell immune response account for relapse of chronic myelogenous leukemia (CML). Inactivation of protein phosphatase 2A (PP2A) is essential for CML-quiescent LSC survival and NK cell antitumor activity. Here we show that MIR300 has antiproliferative and PP2A-activating functions that are dose dependently differentially induced by CCND2/CDK6 and SET inhibition, respectively. MIR300 is upregulated in CML LSCs and NK cells by bone marrow microenvironment (BMM) signals to induce quiescence and impair immune response, respectively. Conversely, BCR-ABL1 downregulates MIR300 in CML progenitors to prevent growth arrest and PP2A-mediated apoptosis. Quiescent LSCs escape apoptosis by upregulating TUG1 long noncoding RNA that uncouples and limits MIR300 function to cytostasis. Genetic and pharmacologic MIR300 modulation and/or PP2A-activating drug treatment restore NK cell activity, inhibit BMM-induced growth arrest, and selectively trigger LSC apoptosis in vitro and in patient-derived xenografts; hence, the importance of MIR300 and PP2A activity for CML development and therapy. SIGNIFICANCE: Tumor-naïve microenvironment–induced MIR300 is the only tumor suppressor miRNA that induces CML LSC quiescence while inhibiting NK cell antitumor immune response, and CML LSC/ progenitor cell apoptosis through its anti-proliferative and PP2A-activating functions, respectively. Thus, the importance of MIR300 and PP2A-activating drugs for formation/survival and eradication of drug-resistant CML LSCs, respectively.
- Published
- 2020
3. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
- Author
-
White, H., Deprez, L., Corbisier, P., Hall, V., Lin, F., Mazoua, S., Trapmann, S., Aggerholm, A., Andrikovics, H., Akiki, S., Barbany, G., Boeckx, N., Bench, A., Catherwood, M., Cayuela, J-M, Chudleigh, S., Clench, T., Colomer, D., Daraio, F., Dulucq, S., Farrugia, J., Fletcher, L., Foroni, L., Ganderton, R., Gerrard, G., Gineikiene, E., Hayette, S., El Housni, H., Izzo, B., Jansson, Mattias, Johnels, P., Jurcek, T., Kairisto, V., Kizilors, A., Kim, D-W, Lange, T., Lion, T., Polakova, K. M., Martinelli, G., McCarron, S., Merle, P. A., Milner, B., Mitterbauer-Hohendanner, G., Nagar, M., Nickless, G., Nomdedeu, J., Nymoen, D. A., Leibundgut, E. O., Ozbek, U., Pajic, T., Pfeifer, H., Preudhomme, C., Raudsepp, K., Romeo, G., Sacha, T., Talmaci, R., Touloumenidou, T., Van der Velden, V. H. J., Waits, P., Wang, L., Wilkinson, E., Wilson, G., Wren, D., Zadro, R., Ziermann, J., Zoi, K., Mueller, M. C., Hochhaus, A., Schimmel, H., Cross, N. C. P., Emons, H., White, H., Deprez, L., Corbisier, P., Hall, V., Lin, F., Mazoua, S., Trapmann, S., Aggerholm, A., Andrikovics, H., Akiki, S., Barbany, G., Boeckx, N., Bench, A., Catherwood, M., Cayuela, J-M, Chudleigh, S., Clench, T., Colomer, D., Daraio, F., Dulucq, S., Farrugia, J., Fletcher, L., Foroni, L., Ganderton, R., Gerrard, G., Gineikiene, E., Hayette, S., El Housni, H., Izzo, B., Jansson, Mattias, Johnels, P., Jurcek, T., Kairisto, V., Kizilors, A., Kim, D-W, Lange, T., Lion, T., Polakova, K. M., Martinelli, G., McCarron, S., Merle, P. A., Milner, B., Mitterbauer-Hohendanner, G., Nagar, M., Nickless, G., Nomdedeu, J., Nymoen, D. A., Leibundgut, E. O., Ozbek, U., Pajic, T., Pfeifer, H., Preudhomme, C., Raudsepp, K., Romeo, G., Sacha, T., Talmaci, R., Touloumenidou, T., Van der Velden, V. H. J., Waits, P., Wang, L., Wilkinson, E., Wilson, G., Wren, D., Zadro, R., Ziermann, J., Zoi, K., Mueller, M. C., Hochhaus, A., Schimmel, H., Cross, N. C. P., and Emons, H.
- Abstract
Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08 +/- 0.13 x 10(6), 1.08 +/- 0.11 x 10(5), 1.03 +/- 0.10 x 10(4), 1.02 +/- 0.09 x 10(3), 1.04 +/- 0.10 x 10(2) and 10.0 +/- 1.5 copies/mu l. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/;CRM code ERM-AD623a-f).
- Published
- 2015
- Full Text
- View/download PDF
4. A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR
- Author
-
White, H, primary, Deprez, L, additional, Corbisier, P, additional, Hall, V, additional, Lin, F, additional, Mazoua, S, additional, Trapmann, S, additional, Aggerholm, A, additional, Andrikovics, H, additional, Akiki, S, additional, Barbany, G, additional, Boeckx, N, additional, Bench, A, additional, Catherwood, M, additional, Cayuela, J-M, additional, Chudleigh, S, additional, Clench, T, additional, Colomer, D, additional, Daraio, F, additional, Dulucq, S, additional, Farrugia, J, additional, Fletcher, L, additional, Foroni, L, additional, Ganderton, R, additional, Gerrard, G, additional, Gineikienė, E, additional, Hayette, S, additional, El Housni, H, additional, Izzo, B, additional, Jansson, M, additional, Johnels, P, additional, Jurcek, T, additional, Kairisto, V, additional, Kizilors, A, additional, Kim, D-W, additional, Lange, T, additional, Lion, T, additional, Polakova, K M, additional, Martinelli, G, additional, McCarron, S, additional, Merle, P A, additional, Milner, B, additional, Mitterbauer-Hohendanner, G, additional, Nagar, M, additional, Nickless, G, additional, Nomdedéu, J, additional, Nymoen, D A, additional, Leibundgut, E O, additional, Ozbek, U, additional, Pajič, T, additional, Pfeifer, H, additional, Preudhomme, C, additional, Raudsepp, K, additional, Romeo, G, additional, Sacha, T, additional, Talmaci, R, additional, Touloumenidou, T, additional, Van der Velden, V H J, additional, Waits, P, additional, Wang, L, additional, Wilkinson, E, additional, Wilson, G, additional, Wren, D, additional, Zadro, R, additional, Ziermann, J, additional, Zoi, K, additional, Müller, M C, additional, Hochhaus, A, additional, Schimmel, H, additional, Cross, N C P, additional, and Emons, H, additional
- Published
- 2014
- Full Text
- View/download PDF
5. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
- Author
-
Van Der Velden, V H J, Cayuela, J-M, McCarron, S, Sacha, T, Fletcher, L, Ziermann, J, Müller, M C, Schimmel, H, El Housni, H, White, H, Farrugia, J, Boeckx, N, Romeo, G, Johnels, P, Zoi, K, Chudleigh, S, Lion, T, Kairisto, V, Deprez, L, Ganderton, R, Merle, P A, Dulucq, S, Pajič, T, Gerrard, G, Martinelli, G, Trapmann, S, Hall, V, Nagar, M, Colomer, D, Hochhaus, A, Kizilors, A, Mitterbauer-Hohendanner, G, Talmaci, R, Gineikienė, E, Oppliger Leibundgut, Elisabeth, Mazoua, S, Cross, N C P, Milner, B, Zadro, R, Lin, F, Foroni, L, Waits, P, Kim, D-W, Nickless, G, Jansson, M, Pfeifer, H, Wilson, G, Raudsepp, K, Clench, T, Daraio, F, Preudhomme, C, Wang, L, Emons, H, Bench, A, Nomdedéu, J, Wilkinson, E, Hayette, S, Jurcek, T, Aggerholm, A, Izzo, B, Lange, T, Akiki, S, Andrikovics, H, Polakova, K M, Corbisier, P, Ozbek, U, Nymoen, D A, Wren, D, Barbany, G, Catherwood, M, and Touloumenidou, T
- Subjects
hemic and lymphatic diseases ,610 Medicine & health ,3. Good health - Abstract
Serial quantification of BCR-ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results reported by different laboratories. To improve comparability, an internationally accepted plasmid certified reference material (CRM) was developed according to ISO Guide 34:2009. Fragments of BCR-ABL1 (e14a2 mRNA fusion), BCR and GUSB transcripts were amplified and cloned into pUC18 to yield plasmid pIRMM0099. Six different linearised plasmid solutions were produced with the following copy number concentrations, assigned by digital PCR, and expanded uncertainties: 1.08±0.13 × 10(6), 1.08±0.11 × 10(5), 1.03±0.10 × 10(4), 1.02±0.09 × 10(3), 1.04±0.10 × 10(2) and 10.0±1.5 copies/μl. The certification of the material for the number of specific DNA fragments per plasmid, copy number concentration of the plasmid solutions and the assessment of inter-unit heterogeneity and stability were performed according to ISO Guide 35:2006. Two suitability studies performed by 63 BCR-ABL1 testing laboratories demonstrated that this set of 6 plasmid CRMs can help to standardise a number of measured transcripts of e14a2 BCR-ABL1 and three control genes (ABL1, BCR and GUSB). The set of six plasmid CRMs is distributed worldwide by the Institute for Reference Materials and Measurements (Belgium) and its authorised distributors (https://ec.europa.eu/jrc/en/reference-materials/catalogue/; CRM code ERM-AD623a-f).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.